Cargando…

Short- and long-term effects of erythropoietin treatment on endothelial progenitor cell levels in patients with cardiorenal syndrome

OBJECTIVE: Patients with cardiorenal syndrome (CRS) have high cardiovascular morbidity. Endothelial progenitor cells (EPC) constitute an endogenous vascular repairsystem, protecting against atherosclerosis development. Erythropoietin (EPO) treatment may have beneficial effects by mobilizing EPC from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jie, Kim E, van der Putten, Karien, Bergevoet, Marloes W T, Doevendans, Pieter A, Gaillard, Carlo A J M, Braam, Branko, Verhaar, Marianne C
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Group 2010
Materias:	Cardiorenal Syndrome
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002834/ https://www.ncbi.nlm.nih.gov/pubmed/21071558 http://dx.doi.org/10.1136/hrt.2010.194654

Ejemplares similares

A journey from microenvironment to macroenvironment: the role of metaflammation and epigenetic changes in cardiorenal disease
por: Kanbay, Mehmet, et al.
Publicado: (2019)

Short-Term Erythropoietin Treatment Does Not Substantially Modulate Monocyte Transcriptomes of Patients with Combined Heart and Renal Failure
por: Jie, Kim E., et al.
Publicado: (2012)

Atherosclerotic renal artery stenosis is prevalent in cardiorenal patients but not associated with left ventricular function and myocardial fibrosis as assessed by cardiac magnetic resonance imaging
por: Emans, Mireille E, et al.
Publicado: (2012)

Epoetin Beta and C‐Terminal Fibroblast Growth Factor 23 in Patients With Chronic Heart Failure and Chronic Kidney Disease
por: Eisenga, Michele F., et al.
Publicado: (2019)

Impaired Endothelial Progenitor Cell Mobilization and Dysfunctional Bone Marrow Stroma in Diabetes Mellitus
por: Westerweel, Peter E., et al.
Publicado: (2013)

Neuronal Nitric Oxide Synthase-Dependent Amelioration of Diastolic Dysfunction in Rats with Chronic Renocardiac Syndrome
por: Bongartz, Lennart G., et al.
Publicado: (2015)

Impact of erythropoietin therapy on cardiorenal syndrome: A systematic review with meta-analysis
por: Bhangal, Rubal, et al.
Publicado: (2023)

Sjögren’s syndrome: state of the art on clinical practice guidelines
por: Romão, Vasco C, et al.
Publicado: (2018)

Health-related quality of life and depression among participants in the Sjögren’s International Collaborative Clinical Alliance registry
por: Chou, Annie, et al.
Publicado: (2017)

Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren’s syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology?
por: Blokland, Sofie L M, et al.
Publicado: (2019)

Locomotive Syndrome: Operational Definition Based on a Questionnaire, and Exercise Interventions on Mobility Dysfunction in Elderly People
por: Akai, M, et al.
Publicado: (2016)

Deciphering the role of cDC2s in Sjögren’s syndrome: transcriptomic profile links altered antigen processes with IFN signature and autoimmunity
por: Lopes, Ana P, et al.
Publicado: (2023)

Salivary Gland Mucosa‐Associated Lymphoid Tissue–Type Lymphoma From Sjögren’s Syndrome Patients in the Majority Express Rheumatoid Factors Affinity‐Selected for IgG
por: Bende, Richard J., et al.
Publicado: (2020)

Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren’s syndrome
por: Nayar, Saba, et al.
Publicado: (2019)

Dysregulated long non-coding RNA in Sjögren’s disease impacts both interferon and adaptive immune responses
por: Joachims, Michelle L, et al.
Publicado: (2022)

Salivary gland secretome: a novel tool towards molecular stratification of patients with primary Sjögren’s syndrome and non-autoimmune sicca
por: Blokland, Sofie L M, et al.
Publicado: (2019)

Weight change over five-year periods and number of components of the metabolic syndrome in a Dutch cohort
por: Bot, M., et al.
Publicado: (2010)

Co-occurrence of Myocardial Sarcoidosis and Left Ventricular Non-compaction in a Patient with Advanced Heart Failure
por: Kumar, Anupam A, et al.
Publicado: (2022)

Patient burden of Sjögren’s: a comprehensive literature review revealing the range and heterogeneity of measures used in assessments of severity
por: Hammitt, Katherine M, et al.
Publicado: (2017)

Lysosome-associated membrane protein 3 misexpression in salivary glands induces a Sjögren’s syndrome-like phenotype in mice
por: Nakamura, Hiroyuki, et al.
Publicado: (2021)

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
por: Rosenthal, A, et al.
Publicado: (2016)

Epigenetic Signatures of Salivary Gland Inflammation in Sjögren's Syndrome
por: Cole, Michael B., et al.
Publicado: (2016)

Proteogenomic analysis of the autoreactive B cell repertoire in blood and tissues of patients with Sjögren’s syndrome
por: Broeren, Mathijs G A, et al.
Publicado: (2022)

Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren’s syndrome that show potential to predict and monitor clinical response
por: Hamkour, Safae, et al.
Publicado: (2023)

Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure
por: van Breda, Fenna, et al.
Publicado: (2015)

Symptom‐Based Cluster Analysis Categorizes Sjögren's Disease Subtypes: An International Cohort Study Highlighting Disease Severity and Treatment Discordance
por: McCoy, Sara S., et al.
Publicado: (2022)

Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren’s Syndrome: A Randomized Clinical Trial
por: Posada, James, et al.
Publicado: (2020)

Sjögren’s and non-Sjögren’s sicca share a similar symptom burden but with a distinct symptom-associated proteomic signature
por: Pucino, Valentina, et al.
Publicado: (2022)

Human cardiomyocyte progenitor cells: a short history of nearly everything
por: Vliet, Patrick, et al.
Publicado: (2012)

Autoantigen TRIM21/Ro52 is expressed on the surface of antigen-presenting cells and its enhanced expression in Sjögren’s syndrome is associated with B cell hyperactivity and type I interferon activity
por: Hillen, Maarten R, et al.
Publicado: (2020)

Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the Discrepancy
por: Bezzina, Oriana M., et al.
Publicado: (2017)

Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren’s syndrome
por: Verstappen, Gwenny M, et al.
Publicado: (2022)

Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome
por: Seror, Raphaele, et al.
Publicado: (2022)

De novo, heterozygous, loss‐of‐function mutations in SYNGAP1 cause a syndromic form of intellectual disability
por: Parker, Michael J., et al.
Publicado: (2015)

Type I IFN system activation in newborns exposed to Ro/SSA and La/SSB autoantibodies in utero
por: Hedlund, Malin, et al.
Publicado: (2020)

Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren’s syndrome
por: Brito-Zerón, Pilar, et al.
Publicado: (2019)

Genome‐Wide Association Analysis Reveals Genetic Heterogeneity of Sjögren's Syndrome According to Ancestry
por: Taylor, Kimberly E., et al.
Publicado: (2017)

Variability of Primary Sjögren's Syndrome Is Driven by Interferon‐α and Interferon‐α Blood Levels Are Associated With the Class II HLA–DQ Locus
por: Trutschel, Diana, et al.
Publicado: (2022)

Strong Association of Combined Genetic Deficiencies in the Classical Complement Pathway With Risk of Systemic Lupus Erythematosus and Primary Sjögren's Syndrome
por: Lundtoft, Christian, et al.
Publicado: (2022)

Syndrome in Question()
por: Orasmo, Cínthia Rosane, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ef61qdnjbn8dkj0q3dljijs85b